138 related articles for article (PubMed ID: 37087399)
1. Impact of Therapy Management on Axitinib-Related Adverse Events in Patients With Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + Checkpoint Inhibitor.
Zakharia Y; Huynh L; Du S; Chang R; Pi S; Sundaresan S; Duh MS; Zanotti G; Thomaidou D
Clin Genitourin Cancer; 2023 Oct; 21(5):e343-e351. PubMed ID: 37087399
[TBL] [Abstract][Full Text] [Related]
2. Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma.
Rini BI; Atkins MB; Choueiri TK; Thomaidou D; Rosbrook B; Thakur M; Hutson TE
Clin Genitourin Cancer; 2021 Oct; 19(5):e306-e312. PubMed ID: 33947608
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
4. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
[TBL] [Abstract][Full Text] [Related]
5. Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial.
Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Tarazi JC; Duggan W; Perini R; Thakur M; Fernandez KC; Choueiri TK
Eur J Cancer; 2021 Mar; 145():1-10. PubMed ID: 33412465
[TBL] [Abstract][Full Text] [Related]
6. Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.
Ornstein MC; Pal SK; Wood LS; Tomer JM; Hobbs BP; Jia XS; Allman KD; Martin A; Olencki T; Davis NB; Gilligan TD; Mortazavi A; Rathmell WK; Garcia JA; Rini BI
Lancet Oncol; 2019 Oct; 20(10):1386-1394. PubMed ID: 31427205
[TBL] [Abstract][Full Text] [Related]
7. Real-World Axitinib Use in the United States: A Retrospective Study Using Linked Datasets.
MacLean E; Cisar L; Mehle K; Eremina D; Quigley JM
J Manag Care Spec Pharm; 2016 Jun; 22(6):723-732u. PubMed ID: 27231799
[TBL] [Abstract][Full Text] [Related]
8. Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial.
Rini BI; Atkins MB; Plimack ER; Soulières D; McDermott RS; Bedke J; Tartas S; Alekseev B; Melichar B; Shparyk Y; Kondoh C; Langiewicz P; Wood LA; Hammers H; Silber CG; Haber B; Jensen E; Chen M; Powles T
Eur Urol Oncol; 2022 Apr; 5(2):225-234. PubMed ID: 34244116
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
Powles T; Plimack ER; Soulières D; Waddell T; Stus V; Gafanov R; Nosov D; Pouliot F; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Bedke J; Tamada S; Yin L; Chen M; Molife LR; Atkins MB; Rini BI
Lancet Oncol; 2020 Dec; 21(12):1563-1573. PubMed ID: 33284113
[TBL] [Abstract][Full Text] [Related]
10. Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T; Nakano Y; Hongo F; Katano H; Miyagawa T; Ueda K; Azuma H; Nozawa M; Hinata N; Hori J; Otoshi T; Shimizu N; Aizawa M; Osada S; Matsui A; Oya M; Eto M; Tomita Y; Shinohara N; Uemura H
Int J Urol; 2024 Mar; 31(3):265-272. PubMed ID: 38110838
[TBL] [Abstract][Full Text] [Related]
11. Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events.
Grünwald V; Voss MH; Rini BI; Powles T; Albiges L; Giles RH; Jonasch E
Br J Cancer; 2020 Sep; 123(6):898-904. PubMed ID: 32587360
[TBL] [Abstract][Full Text] [Related]
12. Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies.
Bracarda S; Castellano D; Procopio G; Sepúlveda JM; Sisani M; Verzoni E; Schmidinger M
Expert Opin Drug Saf; 2014 Apr; 13(4):497-510. PubMed ID: 24641566
[TBL] [Abstract][Full Text] [Related]
13. Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy.
Shin SJ; Lee JL; Kwon TG; Shim BY; Chung HS; Kim SH; Park SH
Cancer Res Treat; 2023 Apr; 55(2):643-651. PubMed ID: 36470258
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101.
Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Uemura H; Albiges L; Fujii Y; Umeyama Y; Wang J; Mariani M; Schmidinger M
ESMO Open; 2022 Apr; 7(2):100450. PubMed ID: 35397432
[TBL] [Abstract][Full Text] [Related]
15. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Motzer RJ; Penkov K; Haanen J; Rini B; Albiges L; Campbell MT; Venugopal B; Kollmannsberger C; Negrier S; Uemura M; Lee JL; Vasiliev A; Miller WH; Gurney H; Schmidinger M; Larkin J; Atkins MB; Bedke J; Alekseev B; Wang J; Mariani M; Robbins PB; Chudnovsky A; Fowst C; Hariharan S; Huang B; di Pietro A; Choueiri TK
N Engl J Med; 2019 Mar; 380(12):1103-1115. PubMed ID: 30779531
[TBL] [Abstract][Full Text] [Related]
16. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma.
Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H
Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a).
Stellato M; Buti S; Maruzzo M; Bersanelli M; Pierantoni F; De Giorgi U; Di Napoli M; Iacovelli R; Vitale MG; Ermacora P; Malgeri A; Maiorano BA; Prati V; Mennitto A; Cavo A; Santoni M; Carella C; Fratino L; Procopio G; Verzoni E; Santini D
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674615
[TBL] [Abstract][Full Text] [Related]
18. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
19. Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma.
McGregor B; Geynisman DM; Burotto M; Porta C; Suarez C; Bourlon MT; Del Tejo V; Du EX; Yang X; Sendhil SR; Betts KA; Huo S
Oncologist; 2023 Jan; 28(1):72-79. PubMed ID: 36124890
[TBL] [Abstract][Full Text] [Related]
20. Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach.
Wood LS; Ornstein MC
JCO Oncol Pract; 2020 Feb; 16(2_suppl):15s-19s. PubMed ID: 32045538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
